title: Development of Leishmania vaccines in the era of visceral leishmaniasis elimination.
abstract: A visceral leishmaniasis (VL) elimination target set for the Indian subcontinent in 2005 is being met in many endemic areas without a vaccine. This begs a question: is a VL vaccine needed if elimination targets can be met with current control programs? Here, we argue that a vaccine will be critical if the success of recent VL control efforts are to be sustained. However, not only do we require a safe and effective vaccine, but we also need to know how this should be used for maximum impact. In particular, identifying appropriate target populations to vaccinate will be crucial.
authors.affiliation: QIMR Berghofer, Brisbane, Australia Christian.Engwerda@qimr.edu.au.
authors.forename: Christian R
authors.initials: CR
authors.lastname: Engwerda
authors.affiliation: Department of Microbiology and Immunology, McGill University, Montreal, Canada.
authors.forename: Greg
authors.initials: G
authors.lastname: Matlashewski
mesh_terms: D060740:Disease Eradication; D006801:Humans; D007194:India; D007893:Leishmania donovani / Q000276:immunology*; D054332:Leishmaniasis Vaccines / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission
chemical_list: D054332:Leishmaniasis Vaccines